- -11%
(edit with the Customer Reassurance module)
(edit with the Customer Reassurance module)
(edit with the Customer Reassurance module)
Superdrol Injectable is Dragon Pharma's injectable formulation of Methyldrostanolone at 40mg/ml in MCT oil β the same active compound as Superdrol 10mg tablets, administered via intramuscular injection to bypass the first-pass hepatic metabolism that drives oral Superdrol's severe hepatotoxicity. For the complete compound background β including the methylated Masteron structure, prohormone history and mechanism β see the oral Superdrol page.
Also searched as: Injectable Superdrol, Methyldrostanolone injection, Superdrol Inj Dragon Pharma, injectable methasterone.
Injectable Methyldrostanolone is unusual β 17-alpha-alkylated compounds are almost exclusively oral because the alkylation's primary purpose is oral bioavailability. The injectable format addresses the oral form's core limitation:
| Parameter | Superdrol Injectable (40mg/ml) | Superdrol Oral (10mg/tab) |
|---|---|---|
| Route | Intramuscular injection | Oral tablet |
| First-pass hepatic exposure | Bypassed β systemic delivery only | 100% first-pass through liver |
| Hepatotoxicity | Reduced β still present systemically | Severe β first-pass concentration |
| Bioavailability | Near-complete via IM | Moderate β first-pass metabolism |
| Convenience | Injection required | Oral tablet β most convenient |
| Dose precision | Volume-based β flexible | Tablet-based β 10mg increments |
| Same anabolic compound | Yes β identical active molecule | Yes |
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| Standard performance | 20β40 mg/day | Daily IM injection | 4β6 weeks maximum |
| Conservative start | 20 mg/day (0.5ml) | Daily | Assess hepatic response before escalating |
At 40mg/ml, a 0.5ml daily injection delivers 20mg; a 1ml injection delivers 40mg. The IM injection route is typically gluteal, vastus lateralis or deltoid β rotating sites daily. Because hepatotoxicity is reduced but not eliminated, cycle length is still strictly limited to 4-6 weeks, which is somewhat longer than the 3-4 week oral cycle maximum due to the reduced first-pass load. Liver enzyme monitoring remains essential throughout.